After a big year, biotech flotations have much to do
Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.
Corporate and regulatory developments over the Christmas period
Myovant and Pfizer showed that deal-making was not taking a Christmas break, but for Celgene CVR holders the dream is almost over. And vaccine approvals gained pace.
2017 rewrites the record books as venture funding accelerates
In terms of venture financing, activity in 2017 outpaced that at the height of the biotech boom in 2015, with 68 biotechs attracted rounds of $50m or more.
